| Azafaros–Schroders: investment, 202505 financing round Series B totalling €132m incl existing + co-investor Schroders Capital |
2025-05-13 |
| Azafaros–Seroba: investment, 202505 financing round Series B totalling €132m incl new + co-investor Seroba |
2025-05-13 |
| Azafaros–SEVERAL: investment, 202505 financing round Series B €132m led by Jeito Capital + co-led by Forbion Growth |
2025-05-13 |
| Haya Therapeutics–Schroders: investment, 202505 financing round Series A totalling $65m incl existing + co-investor Schroders Capital |
2025-05-08 |
| Haya Therapeutics–SEVERAL: investment, 202505 financing round Series A $65m led by Sofinnova Partners + Earlybird VC |
2025-05-08 |
| Boehringer–Tessellate Bio: cancer drugs, 202504– collab research + license ww up to >€500m precision treatments for hard-to-treat cancers |
2025-04-23 |
| Biotage–KKR: investment, 202504– public takeover offer by RWK BidCo AB valuing Biotage at SEK11.6b at SEK1.65/share (KKR already owns 17%) |
2025-04-22 |
| Alis Biosciences–Optimum Strategic Communications: public relations, 202504 service existent by Optimum |
2025-04-18 |
| Glycomine–SEVERAL: investment, 202504 financing round Series C $115m led by CTI Life Sciences Fund + abrdn Inc + Advent Life Sciences |
2025-04-16 |
| Astellas–Chromatin Bioscience: synthetic promoters, 202504– collab using chromatinLENS platform to design promoters aligned w Astellas’ target profile |
2025-04-14 |
| 1st PhileKorea–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in South Korea by 1st PhileKorea |
2025-04-09 |
| As One Corp–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Japan by 1st PhileKorea |
2025-04-09 |
| Bang Trading–Sphere Bio: cell analysis technology, 202504 distribution existent for Sphere Bio in Thailand by Bang Trading |
2025-04-09 |
| Cold Spring Biotech–Sphere Bio: cell analysis technology, 202504 distribution existent for Sphere Bio in Taiwan by Cold Spring Biotech |
2025-04-09 |
| Decode Science–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Australia + New Zealand by Decode Science |
2025-04-09 |
| Everlife Research Instruments–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Singapore by Everlife |
2025-04-09 |
| Gene Company–Sphere Bio: cell analysis technology, 202504 distribution existent for Sphere Bio in China + Hong Kong by Gene Company |
2025-04-09 |
| Immunic–Aberdeen Group: investment, 202504 registered directed offering totalling $5.1m incl lead investor Aberdeen Investments |
2025-04-09 |
| Immunic–SEVERAL: investment, 202504 registered directed offering $5.1m led by Aberdeen Investments with 5.67m shares common stock at $0.9/share |
2025-04-09 |
| Premas Life Sciences–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in India + Bangladesh by Premas Life Sciences |
2025-04-09 |
| Dotmatics–Siemens: investment, 202402– acquisition $5.1b of Dotmatics from Insight Partners ANNOUNCED |
2025-04-02 |
| Nuage Therapeutics–Vigo Consulting: public relations, 202504 service existent by Vigo Consulting |
2025-04-01 |
| Isomorphic Labs–Alphabet: investment, 202503 first external financing round totalling $600m incl co-investor GV |
2025-03-31 |
| Isomorphic Labs–Alphabet: investment, 202503 first external financing round totalling $600m incl existing + co-investor Alphabet |
2025-03-31 |
| Isomorphic Labs–SEVERAL: investment, 202503 first external financing round $600m led by Thrive Capital |
2025-03-31 |
| Isomorphic Labs–Thrive Capital: investment, 202503 first external financing round totalling $600m incl lead investor Thrive Capital |
2025-03-31 |
| Amboss–Lightrock: investment, 202503 financing round totalling €240m incl new + co-lead investorLightrock |
2025-03-25 |
| Amboss–M&G: investment, 202503 financing round totalling €240m incl new + co-lead investor M&G Investments |
2025-03-25 |
| Amboss–OTHER: investment, 202503 financing round totalling €240m incl existing investors as co-investors |
2025-03-25 |
| Amboss–SEVERAL: investment, 202503 financing round €240m led by Kirkbi + M&G Investments + Lightrock |
2025-03-25 |
| AstraZeneca–Beijing (govt): business park, 202503– strategic partnership involving $2.5b investment by AstraZeneca in Beijing BioPark + collaborations |
2025-03-21 |
| AstraZeneca–Beijing Cancer Hospital: cancer drugs, 202503– strategic partnership in translational research + data science + clinical development |
2025-03-21 |
| AstraZeneca–BioKangtai: vaccines, 202503– collab joint venture in Beijing to develop + manufacture + commercialise vaccines |
2025-03-21 |
| AstraZeneca–Harbour BioMed: therapeutic antibodies, 202503– collab + license agreem to discover multi-specific antibodies |
2025-03-21 |
| AstraZeneca–Syneron Bio: peptide therapeutics, 202503– collab + license agreem to develop macrocyclic peptides |
2025-03-21 |
| Thena Capital–SEVERAL: investment, 202503 first close £27m of in augural UK MedTech Fund with cornerstone commitment from British Business Bank |
2025-03-21 |
| Roche–Oxford BioTherapeutics: antibody cancer drugs, 202503– collab strategic $36m upfront + >$1b milestones using OGAP Verify for Ab cancer drugs |
2025-03-19 |
| Forth Therapeutics–SEVERAL: investment, 202503 launch with seed investment round from Sofinnova Partners + Old College Capital |
2025-03-18 |
| Forth Therapeutics–Sofinnova: investment, 202503 launch with seed investment round incl founding investor Sofinnova Biovelocita II fund |
2025-03-18 |
| Forth Therapeutics–Univ Edinburgh: investment, 202503 launch with seed investment round incl founding investor Old College Capital |
2025-03-18 |
| AstraZeneca–Alteogen: drug delivery technology, 202503– license ww + supply to use ALT-B4 to develop + market sc formulations of cancer drugs |
2025-03-17 |
| EsoBiotec–AstraZeneca: investment, 202503 acquisition $425m upfront + $575m milestones on cash/debt free basis |
2025-03-17 |
| Chimerix–Jazz Pharmaceuticals: investment, 202503– acquisition cash tender offer $935m at $8.55/share by Jazz Pharmaceuticals |
2025-03-05 |
| Epoch Biodesign–Extantia Capital: investment, 202503 financing round Series A totalling $17.3m incl lead investor Extantia Capital |
2025-03-05 |
| Epoch Biodesign–SEVERAL: investment, 202503 financing round Series A $17.3m led by Extantia Capital |
2025-03-05 |
| Epoch Biodesign–United Kingdom (govt): grant, 202503c grant $1m from UK govt |
2025-03-05 |
| Trimtech Therapeutics–SEVERAL: investment, 202503 seed financing round £25m led by Cambridge Innovationn Capital + DDF |
2025-03-05 |
| Xund Solutions–SEVERAL: investment, 202503 financing round pre-Series A €6m led by Lead Ventures |
2025-03-05 |
| FibroGen–AstraZeneca: investment, 202502 acquisition $160m (incl acquired net cash of $75m) of FibroGen China by AZ incl rights to roxadustat in China |
2025-02-20 |
| Anbio Biotechnology–SEVERAL: investment, 202502 IPO $8m net $7.44m at Nasdaq Global Market with 1.6m Class A ordinary shares at $5/share |
2025-02-18 |
| Novartis–Isomorphic Labs: AI-based drug discovery, 202502– collab expansion adding up to 3 research programs same financial terms as agreem in 1/24 |
2025-02-18 |
| Latent Labs–SEVERAL: investment, 202502 financing round Series A $40m co-led by Radical Ventures + Sofinnova Partners |
2025-02-13 |
| Latent Labs–SEVERAL: investment, <202502 financing round pre-Series A? $10m incl 8VC + Kindred Capital + Pillar VC |
2025-02-13 |
| Ochre Bio–Som.X: public relations, 202502 service existent? Ochrebio listed as client at web site |
2025-02-13 |
| Ori Biotech–Som.X: public relations, 202502 service existent? Oribiotech listed as client at web site |
2025-02-13 |
| Pfizer–Som.X: public relations, 202502 service existent? Pfizer listed as client at web site |
2025-02-13 |
| Avalyn Pharma–Qureight: drug development services, 202502– collab using Qureight imaging technology in multiple Avalyn clinical studies |
2025-02-05 |
| Qureight–Som.X: public relations, 202502 service existent SomX is media contact for Qureight |
2025-02-05 |
| Akribion–Optimum Strategic Communications: public relations, 202502 service existent by Optimum |
2025-02-04 |
| Quibim–SEVERAL: investment, 202501 financing round Series A $50m led by Asabys + Beunavista Equity Partners |
2025-01-28 |
| 4basebio–Circio: synthetic DNA vectors, 202501– collab developm integration of circVEC system with Hermes platform + hpDNA + opDNA |
2025-01-21 |
| JnJ–Chromatin Bioscience: synthetic promoter design, 202501– collab leveraging chromatinLENS platform |
2025-01-20 |
| Zwisler Laboratorium–Cormica: investment, 202501 acquisition of Zwisler Laboratorium GmbH by Cormica |
2025-01-20 |
| EsoBiotec–Chromatin Bioscience: synthetic promoters, –202501– collab existent using chromatinLENS platform to design promoters for EsoBiotec |
2025-01-17 |
| Owlstone–Aviva: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Aviva Ventures |
2025-01-15 |
| Owlstone–Gates Foundation: grant, 202404– initial $1.5m grant to develop breat-based diagnostics for developing countries from Gates Foundation |
2025-01-15 |
| Owlstone–Horizons Ventures: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Horizon Ventures |
2025-01-15 |
| Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital |
2025-01-15 |
| Owlstone–Ventura Capital: investment, 202501 financing round Series E first closing totalling $27m incl existing + lead investor Ventura Capital |
2025-01-15 |
| Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation |
2025-01-14 |
| IDRx–GSK: investment, 202501– acquisition 100% of IDRx for $1b upfront + $150m milestones by GSK |
2025-01-13 |
| Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities |
2025-01-10 |
| Windward Bio–SR One: investment, 202501 financing round Series A totalling $200m incl co-investor SR One |
2025-01-10 |
| Coave Therapeutics–Seroba: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Seroba Life Sciences |
2025-01-09 |
| Coave Therapeutics–SEVERAL: investment, 202501 financing round Series A €32m co-led by Novo Holdings + Bpifrance InnoBio |
2025-01-09 |
| Pregene Biopharma–EsoBiotec: CAR T-cell therapy, 202501 collab existent development of ESO-T01 (in China?) |
2025-01-08 |
| Ottimo Pharma–Avoro Capital: investment, 202412 financing round Series A totalling >$140m incl co-lead investor Avoro Capital |
2024-12-19 |
| Ottimo Pharma–Decheng Capital: investment, 202412 financing round Series A totalling >$140m incl co-investor Decheng Capital |
2024-12-19 |
| Ottimo Pharma–Invus Group: investment, 202412 financing round Series A totalling >$140m incl co-investor Invus |
2024-12-19 |
| Ottimo Pharma–Janus Henderson: investment, 202412 financing round Series A totalling >$140m incl co-investor Janus Henderson Investors |
2024-12-19 |
| Ottimo Pharma–JPMorgan Chase: investment, 202412 financing round Series A totalling >$140m incl co-investor JP Morgan Life Sciences Private Capital |
2024-12-19 |
| Ottimo Pharma–Medicxi Ventures: investment, 202412 financing round Series A totalling >$140m incl existing + co-investor Medicxi |
2024-12-19 |
| Ottimo Pharma–OrbiMed: investment, 202412 financing round Series A totalling >$140m incl co-lead investor OrbiMed |
2024-12-19 |
| Ottimo Pharma–RTW Investments: investment, 202412 financing round Series A totalling >$140m incl co-investor RTW Investments |
2024-12-19 |
| Ottimo Pharma–Samsara BioCapital: investment, 202412 financing round Series A totalling >$140m incl co-lead investor Samsara BioCapital |
2024-12-19 |
| Ottimo Pharma–SEVERAL: investment, 202412 financing round Series A >$140m led by OrbiMed + Avoro Capital + Samsara BioCapital |
2024-12-19 |
| VectorY–Vigo Consulting: public relations, 202412 service existent by Vigo Consulting |
2024-12-16 |
| Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments |
2024-12-12 |
| BenevolentAI–ICR: public relations, 202412 service existent by ICR Healthcare Europe |
2024-12-11 |
| Fresenius–Ori Biotech: CGT manufacturing technology, 202412– collab integration IRO platform with up + downstream processing tech of Fresenius Kabi |
2024-12-10 |
| GSK–Relation Therapeutics: drug target discovery, 202412– two collab $30m upfront + $263m milestones + royalties in fibrotic diseases + osteoarthritis |
2024-12-10 |
| Relation Therapeutics–GSK: investment, 202412 equity investment $15m in connection with strategic collaborations |
2024-12-10 |
| Citryll–ICR: public relations, 202412 service existent by ICR Healthcare Europe |
2024-12-09 |
| GSK–Muna Therapeutics: drug target discovery, 202412– collab strategic alliance €33.5m upfront + milestones MiND-MAP platform for Alzheimer targets |
2024-12-05 |
| Newcells Biotech–SEVERAL: investment, 202412 financing round £1.2m from existing investors Mercia Ventures + Northstar Ventures + North East Finance |
2024-12-05 |
| HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures |
2024-12-04 |
| HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures |
2024-12-04 |
| Cradle Bio–Index Ventures: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Index Ventures |
2024-11-26 |
| Cradle Bio–Institutional Venture Partners: investment, 202411 financing round Series B totalling $73m incl new + lead investor IVP |
2024-11-26 |
| Cradle Bio–Kindred Capital: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Kindred Capital |
2024-11-26 |
![[LSUK] Life-Sciences-UK.com - The UK Life Sciences Web Portal](/images/basics/lsuk-life-sciences-uk-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
